Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03445104 · ClinicalTrials.gov registry record · Early Phase 1
Effect of Huperzine A on Cognitive Function and Perception of Effort During Exercise
A Early Phase 1 study of Cognitive Enhancement During Exercise, sponsored by St. Louis University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT03445104: Completed Early Phase 1 study of Cognitive Enhancement During Exercise, sponsored by St. Louis University.
NCT03445104 is a Early Phase 1 study of Cognitive Enhancement During Exercise that has completed, run by St. Louis University. The registered enrollment target is 15 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03445104, a Early Phase 1 study of Cognitive Enhancement During Exercise, has completed, sponsored by St. Louis University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates the effects of acute huperzine A ingestion prior to exercise on cognitive function and perceived effort in exercise-trained individuals. Huperzine A has shown the ability to improve cognitive function in dementia patients, and is currently marketed as a cognitive enhancing supplement. Study participants will receive either huperzine A or placebo during the first experimental session, and will receive the other substance during the second session.
Primary Outcome
Digit span will be used as a measure of working memory. During a period of two minutes, the participants will be presented with a series of digits at a rate of one digit per second, and will be required to to repeat them verbatim. If they succeed, they will be presented with a longer series by one digit. The longest series that they are able to correctly repeat will be the number of their score (i.e. if they are able to repeat a series of 7 digits, their score will be 7).
Conditions Studied
Interventions
- OTHER Placebo
- OTHER Huperzine A
Study Locations (1)
Missouri
- Allied Health Professional Building - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2018-01-16 |
| Est. Completion | 2018-04-05 |
| Phase | Early Phase 1 |
What the finished NCT03445104 record still lists
NCT03445104 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Cognitive Enhancement During Exercise appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03445104 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT03445104 about?
NCT03445104 is a clinical study titled "Effect of Huperzine A on Cognitive Function and Perception of Effort During Exercise". This study evaluates the effects of acute huperzine A ingestion prior to exercise on cognitive function and perceived effort in exercise-trained individuals. Huperzine A has shown the ability to improve cognitive function in dementia patients, and is currently marketed as a cognitive enhancing suppl...
What is the current status of trial NCT03445104?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2018-01-16. Estimated completion is 2018-04-05.
What conditions does trial NCT03445104 study?
This clinical trial studies the following conditions: Cognitive Enhancement During Exercise.
What interventions are being tested in trial NCT03445104?
The interventions under investigation include: Placebo (OTHER), Huperzine A (OTHER).
Who is sponsoring clinical trial NCT03445104?
This trial is sponsored by St. Louis University, which has 107 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03445104 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03445104's enrollment target sits among peer trials
15 1404th of 2000 higher than 527 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI